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Background:  Peroxisome proliferator-activated receptor-gamma (PPARg) agonists improve insulin resistance and exert anti-inflammatory, anti-
oxidative and anti-proliferative effects on vascular wall cells. Aim of the study was to assess the action of different PPARg agonists on endothelial- 
(EC) and vascular smooth muscle cell (VSMC) differentiation and proliferation in murine embryonic stem cells.
Methods:  Embryoid bodies from CGR8 mouse stem cells were plated on day 4 and incubated with rosiglitazone 10 μM and ciglitazone 10μM 
either alone or in co-incubation with the PPARg antagonist GW9662 (10 μM). Differentiation of EC was assessed on days 12, 14, 16 and 18 by 
confocal laser scanning microscopy with CD31 staining. VSMC was stained with alpha smooth muscle actin (aSMC) and quantified by western blot 
on days 12 and 18.
Results:  As shown in Fig. 1, rosiglitazone induced a stronger inhibition of EC differentiation at all time points as compared to ciglitazone. On the 
contrary, proliferation of VSMC at western blot was significantly stronger inhibited after incubation with ciglitazone alone. This finding was not fully 
reversed under co-incubation with the PPARg antagonist GW9662.
Conclusions:  PPARg agonist ciglitazone selectively suppresses VSMC growth with less inhibition of EC differentiation compared to rosiglitazone, 
possibly due to specific pleiotropic effects beyond PPARg activation. Thus, ciglitazone might be useful as a local therapy to inhibit restenosis after 
stent implantation. 
